Clinical Trial Update: A Phase 2a Dose Escalation Study With SLV334 in Patients With Traumatic Brain Injury. [Phase 2]

View source ↗

Summary

A Phase 2a dose-escalation trial of SLV334 in patients with traumatic brain injury has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• SLV334

Snippet

Sponsor: Abbott Products | Conditions: Traumatic Brain Injury | Phase 2 | Status: TERMINATED